
Research from the lab of Andrew Miranker (MB&B) is getting wide attention, with coverage in ScienceAlert and The Independent. In a new Communications Biology paper, Miranker’s team and collaborators at Columbia, Cambridge and Virscio, Inc. studied African green monkeys, which, like humans, naturally develop Alzheimer’s-like amyloid and tau pathology with age. The animals were given synthetic amyloid-beta oligomers, the small protein clusters thought to harm neurons before larger plaques form.
The monkeys showed no decline on a memory task, even a year later. But proteomic analysis of their cerebrospinal fluid and fluid-derived extracellular vesicles told a different story. The treated animals showed persistent, Alzheimer’s-like changes, including elevated immune-response proteins and reduced synapse-associated proteins. The team also developed a workflow that works with under 1 mL of fluid, comparable to a human liquid biopsy.
The findings suggest that biochemical changes can persist long before behavior is affected. That points toward new approaches for early detection and disease tracking, and possibly toward protective mechanisms that limit progression. As lead author and MB&B postdoc Bianca Brown cautions, not every molecular change seen in the monkeys should be assumed to reflect early Alzheimer’s in humans. The study was small, and the next step is comparing these signatures with human samples.
Congratulations to Andrew, Bianca (co-first author with Xiaoting Li of Columbia), and the whole team, including MB&B’s Monica Grasty, Isabel Lopez, Sara Dzigurski and Maya Geradi!
Read the paper here: https://doi.org/10.1038/s42003-026-10968-5